Stay updated on Yttrium90 Ipilimumab Nivolumab in Uveal Melanoma Clinical Trial
Sign up to get notified when there's something new on the Yttrium90 Ipilimumab Nivolumab in Uveal Melanoma Clinical Trial page.

Latest updates to the Yttrium90 Ipilimumab Nivolumab in Uveal Melanoma Clinical Trial page
- ChecktodayChange DetectedThe site revision label was updated from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check7 days agoChange DetectedThe clinical trial page now displays the study record for Yttrium-90, ipilimumab, and nivolumab in uveal melanoma with liver metastases, including study details, eligibility criteria, treatment arms, outcomes, and locations.SummaryDifference50%

- Check14 days agoChange DetectedThe displayed site revision changes from v3.7.2 to v3.8.0 while the page remains a 403 Forbidden screen.SummaryDifference0.2%

- Check28 days agoChange DetectedAn NIH banner announces a terminology transition from “Artificial Intelligence” to “Super Intelligence,” while the site revision advances from v3.7.1 to v3.7.2. The study record itself remains a 403 error page.SummaryDifference1%

- Check42 days agoChange DetectedThe footer now displays site revision v3.7.1 instead of v3.7.0; the page remains a 403 error page.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the study record content with an access-restricted message.SummaryDifference18%

Stay in the know with updates to Yttrium90 Ipilimumab Nivolumab in Uveal Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Yttrium90 Ipilimumab Nivolumab in Uveal Melanoma Clinical Trial page.